Why the study?
Multi-organ dysfunction can occur after acute Stanford type A aortic dissection (AAAD) surgery, motivating a direct comparison of remimazolam and dexmedetomidine for postoperative sedation in these patients.
Does remimazolam improve postoperative sedation (percentage of duration within a target RASS score of -3 to 0) compared to dexmedetomidine in patients undergoing acute Stanford type A aortic dissection surgery?
Does remimazolam improve postoperative sedation (percentage of duration within a target RASS score of -3 to 0) compared to dexmedetomidine in patients undergoing acute Stanford type A aortic dissection surgery?
Remimazolam provided a higher percentage of time within the target postoperative sedation range than dexmedetomidine with comparable adverse events in patients recovering from acute Stanford type A aortic dissection repair.
Answers are grounded in this paper and cite their sources.
Remimazolam achieved superior target sedation maintenance versus dexmedetomidine post-AAAD repair; extends RCT evidence for its use in high-risk aortic surgery.
Introduction Multi-organ dysfunction can occur in patients following acute Stanford type A aortic dissection (AAAD) surgery. We aimed to evaluate the use of remimazolam versus dexmedetomidine for sedation in postoperative AAAD patients. Methods This single-center, prospective, double-blind, randomized controlled trial was conducted between July 2021 and July 2023. Patients undergoing AAAD repair were randomly assigned to receive either remimazolam or dexmedetomidine, and the patients’ sedation level was then evaluated utilizing the Richmond Agitation and Sedation Scale (RASS). The primary study outcome was the percentage of duration during which the patients maintained a targeted RASS score between −3 and 0. The secondary study outcomes included an exploratory analysis of the percentage of the total intervention duration during which the patients maintained a targeted optimal RASS score between −2 and 0, the mechanical ventilation and sedation durations, pain intensity, length of stay in the intensive care unit and hospital stay, Acute Physiologic Assessment and Chronic Health Evaluation II score, and laboratory test results. Results In total, 524 patients were included in the study, with 262 patients in each of the remimazolam and dexmedetomidine groups, and these were all included in the intention-to-treat analysis. The patients’ baseline characteristics and sedative infusion durations were similar between the two groups ( p > 0.05). The time-weighted percentages within the target RASS range of −3–0 were 85.7% (interquartile range 77.8–94.7) and 81.7% (interquartile range 70.0–91.7) in the remimazolam and dexmedetomidine groups, respectively, with a median inter-group difference of 4.0% (95% confidence interval: 0.0–8.5; p = 0.016), while the percentage duration in the optimal RASS range was higher in the remimazolam group than in the dexmedetomidine group (87.5% vs. 85.1%, p = 0.009). Otherwise, the two groups showed comparable results for the other secondary outcomes and adverse events. Conclusions Remimazolam could provide safe and better overall postoperative sedation than dexmedetomidine in patients undergoing AAAD surgery. Clinical Trial Registration Chinese Clinical Trial Registry (chictr.gov, registration number: ChiCTR2100048540).
No takes yet. Share an insight, caveat, or question.
史博伦 et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: